{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T03:24:28Z","timestamp":1792812268876,"version":"4.5.0"},"reference-count":36,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T00:00:00Z","timestamp":1774310400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007560","name":"Chiesi Farmaceutici","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007560","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","resmedjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Respiratory Medicine"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.rmed.2026.108743","type":"journal-article","created":{"date-parts":[[2026,2,28]],"date-time":"2026-02-28T07:44:22Z","timestamp":1772264662000},"page":"108743","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["BDP\/FF\/GB single-inhaler triple therapy in COPD: real-world effectiveness, safety, and adherence in a pooled analysis of 5,000 patients"],"prefix":"10.1016","volume":"254","author":[{"given":"Guy","family":"Brusselle","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9256-9656","authenticated-orcid":false,"given":"Petros","family":"Bakakos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daiana","family":"Stolz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8029-2159","authenticated-orcid":false,"given":"Alessio","family":"Piraino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Franzini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Nudo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-3680-2162","authenticated-orcid":false,"given":"Luca","family":"Di Palma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7801-5040","authenticated-orcid":false,"given":"Paola","family":"Rogliani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.rmed.2026.108743_bib3","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/S2213-2600(21)00511-7","article-title":"Global, regional, and national prevalence of, and risk factors for, chronic obstructive pulmonary disease (COPD) in 2019: a systematic review and modelling analysis","volume":"10","author":"Adeloye","year":"2022","journal-title":"Lancet Respir. Med."},{"issue":"1","key":"10.1016\/j.rmed.2026.108743_bib4","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1186\/s12889-024-17686-9","article-title":"Estimating the global prevalence of chronic obstructive pulmonary disease (COPD): a systematic review and meta-analysis","volume":"24","author":"Al Wachami","year":"2024","journal-title":"BMC Public Health"},{"issue":"11","key":"10.1016\/j.rmed.2026.108743_bib5","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1164\/rccm.202204-0671PP","article-title":"Definition and nomenclature of chronic obstructive pulmonary disease: time for its revision","volume":"206","author":"Celli","year":"2022","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"2","key":"10.1016\/j.rmed.2026.108743_bib6","doi-asserted-by":"crossref","first-page":"13","DOI":"10.11648\/j.ijcems.20160202.11","article-title":"Chronic obstructive pulmonary disease: an overview of epidemiology, pathophysiology, diagnosis, staging and management","volume":"2","author":"Akwe","year":"2016","journal-title":"IJCEMS"},{"key":"10.1016\/j.rmed.2026.108743_bib7","first-page":"391","article-title":"When to use single-inhaler triple therapy in COPD: a practical approach for primary care health care professionals","volume":"14","author":"Gaduzo","year":"2019","journal-title":"COPD J. Chronic Obstr. Pulm. Dis."},{"issue":"10048","key":"10.1016\/j.rmed.2026.108743_bib9","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1016\/S0140-6736(16)31354-X","article-title":"Single inhaler triple therapy versus inhaled corticosteroid plus long-acting \u03b22-agonist therapy for chronic obstructive pulmonary disease (TRILOGY): a double-blind, parallel group, randomised controlled trial","volume":"388","author":"Singh","year":"2016","journal-title":"Lancet"},{"issue":"10082","key":"10.1016\/j.rmed.2026.108743_bib10","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1016\/S0140-6736(17)30188-5","article-title":"Single inhaler extrafine triple therapy versus long-acting muscarinic antagonist therapy for chronic obstructive pulmonary disease (TRINITY): a double-blind, parallel group, randomised controlled trial","volume":"389","author":"Vestbo","year":"2017","journal-title":"Lancet"},{"issue":"10125","key":"10.1016\/j.rmed.2026.108743_bib11","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1016\/S0140-6736(18)30206-X","article-title":"Extrafine inhaled triple therapy versus dual bronchodilator therapy in chronic obstructive pulmonary disease (TRIBUTE): a double-blind, parallel group, randomised controlled trial","volume":"391","author":"Papi","year":"2018","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.rmed.2026.108743_bib12","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1186\/s12931-021-01683-2","article-title":"Efficacy and safety of single-inhaler extrafine triple therapy versus inhaled corticosteroid plus long-acting beta2 agonist in eastern Asian patients with COPD: the TRIVERSYTI randomised controlled trial","volume":"22","author":"Zheng","year":"2021","journal-title":"Respir. Res."},{"key":"10.1016\/j.rmed.2026.108743_bib13","first-page":"79","article-title":"Comparison of dry-powder inhaler and pressurized metered-dose inhaler formulations of extrafine beclomethasone dipropionate\/formoterol fumarate\/glycopyrronium in patients with COPD: the TRI-D randomized controlled trial","volume":"16","author":"Beeh","year":"2021","journal-title":"COPD J. Chronic Obstr. Pulm. Dis."},{"key":"10.1016\/j.rmed.2026.108743_bib14","doi-asserted-by":"crossref","DOI":"10.3238\/arztebl.m2023.0027","article-title":"The diagnosis and treatment of COPD and its comorbidities","author":"Kahnert","year":"2023","journal-title":"Deutsches \u00c4rzteblatt international"},{"issue":"1","key":"10.1016\/j.rmed.2026.108743_bib15","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1186\/s12931-024-02672-x","article-title":"Eligibility of patients with chronic obstructive pulmonary disease for inclusion in randomised control trials investigating triple therapy: a study using routinely collected data","volume":"25","author":"Whittaker","year":"2024","journal-title":"Respir. Res."},{"key":"10.1016\/j.rmed.2026.108743_bib16","doi-asserted-by":"crossref","DOI":"10.1016\/j.rmed.2021.106398","article-title":"TRICOP \u2013 a real-world effectiveness study with a single-inhaler extrafine triple therapy over 52 weeks in Austrian patients with COPD","volume":"182","author":"Marth","year":"2021","journal-title":"Respir. Med."},{"key":"10.1016\/j.rmed.2026.108743_bib17","first-page":"3019","article-title":"Effectiveness of extrafine single inhaler triple therapy in chronic obstructive pulmonary disease (COPD) in Germany \u2013 the TriOptimize study","volume":"17","author":"Gessner","year":"2022","journal-title":"COPD J. Chronic Obstr. Pulm. Dis."},{"key":"10.1016\/j.rmed.2026.108743_bib18","doi-asserted-by":"crossref","DOI":"10.1016\/j.rmed.2023.107219","article-title":"Extrafine single inhaler triple therapy effect on health status, lung function and adherence in COPD patients: a panhellenic prospective non-interventional study \u2013 the TRIBUNE study","volume":"212","author":"Porpodis","year":"2023","journal-title":"Respir. Med."},{"key":"10.1016\/j.rmed.2026.108743_bib19","doi-asserted-by":"crossref","DOI":"10.1016\/j.rmed.2023.107368","article-title":"Evolving to a single inhaler extrafine LABA\/LAMA\/ICS \u2013 inhalation technique and adherence at the heart of COPD patient care (TRIVOLVE)","volume":"218","author":"Brusselle","year":"2023","journal-title":"Respir. Med."},{"key":"10.1016\/j.rmed.2026.108743_bib20","first-page":"475","article-title":"TRITRIAL: the impact of fixed triple therapy with beclometasone\/formoterol\/glycopyrronium on health status and adherence in chronic obstructive pulmonary disease in an Italian context of real life","volume":"19","author":"Richeldi","year":"2024","journal-title":"COPD J. Chronic Obstr. Pulm. Dis."},{"issue":"10","key":"10.1016\/j.rmed.2026.108743_bib21","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1016\/j.rmr.2024.10.003","article-title":"Utilisation en vie r\u00e9elle d\u2019une triple th\u00e9rapie fixe dans la BPCO : \u00e9tude Trilife. Triple association fixe b\u00e9clometasone\/formot\u00e9rol\/glycopyrronium en particules extra-fines","volume":"41","author":"Roche","year":"2024","journal-title":"Rev. Mal. Respir."},{"issue":"3","key":"10.1016\/j.rmed.2026.108743_bib22","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1183\/09031936.00102509","article-title":"Development and first validation of the COPD assessment test","volume":"34","author":"Jones","year":"2009","journal-title":"Eur. Respir. J."},{"issue":"3","key":"10.1016\/j.rmed.2026.108743_bib23","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/S2213-2600(14)70001-3","article-title":"Minimum clinically important difference for the COPD assessment test: a prospective analysis","volume":"2","author":"Kon","year":"2014","journal-title":"Lancet Respir. Med."},{"issue":"2","key":"10.1016\/j.rmed.2026.108743_bib24","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1089\/jamp.2015.1212","article-title":"Validation of the \u2018Test of the Adherence to Inhalers\u2019 (TAI) for asthma and COPD patients","volume":"29","author":"Plaza","year":"2016","journal-title":"J. Aerosol Med. Pulm. Drug Deliv."},{"key":"10.1016\/j.rmed.2026.108743_bib25","first-page":"205","article-title":"Real-world effectiveness of fluticasone furoate\/umeclidinium\/vilanterol once-daily single-inhaler triple therapy for symptomatic COPD: the ELLITHE non-interventional trial","volume":"19","author":"Beeh","year":"2024","journal-title":"COPD J. Chronic Obstr. Pulm. Dis."},{"issue":"2","key":"10.1016\/j.rmed.2026.108743_bib26","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1183\/23120541.00950-2020","article-title":"INTREPID: single- versus multiple-inhaler triple therapy for COPD in usual clinical practice","volume":"7","author":"Halpin","year":"2021","journal-title":"ERJ Open Res"},{"key":"10.1016\/j.rmed.2026.108743_bib27","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.2147\/COPD.S511334","article-title":"Real-world effectiveness of triple extrafine fixed-dose combination with beclomethasone\/formoterol\/glycopyrronium on symptoms and lung function in COPD: a systematic review and meta-analysis","volume":"20","author":"Rogliani","year":"2025","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"issue":"1","key":"10.1016\/j.rmed.2026.108743_bib28","first-page":"111","article-title":"Minimal clinically important differences in COPD lung function","volume":"2","author":"Donohue","year":"2005","journal-title":"COPD J. Chronic Obstr. Pulm. Dis."},{"issue":"2","key":"10.1016\/j.rmed.2026.108743_bib29","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1183\/09031936.00099306","article-title":"Outcomes for COPD pharmacological trials: from lung function to biomarkers","volume":"31","author":"Cazzola","year":"2008","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.rmed.2026.108743_bib30","doi-asserted-by":"crossref","unstructured":"Erminia Ridolo, Manlio Milanese, Alessandro Barone, Francesca Nicoletta, Martina Ottoni, Filippo Ferdinando Cosini, Giovanni Passalacqua, and Carlo Lombardi. Extrafine formulation of beclomethasone dipropionate\/formoterol fumarate\/glycopyrronium bromide delivered via pressurized metered-dose inhaler in the treatment of asthma: a review. Respiratory Disease. 19. doi:10.1177\/17534666251332076.[Check atl content \"Extrafine formulation of beclomethasone dipropionate\/formoterol fumarate\/glycopyrronium bromide delivered via pressurized metered-dose inhaler in the treatment of asthma: a review\" found. But not styled, Check au6 style(s) incorrectly styled in the reference, Check \"stl\" wrongly styled as \"sbtl\"].","DOI":"10.1177\/17534666251332076"},{"issue":"5","key":"10.1016\/j.rmed.2026.108743_bib31","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1111\/bph.14909","article-title":"Beclomethasone dipropionate, formoterol fumarate and glycopyrronium bromide: synergy of triple combination therapy on human airway smooth muscle Ex vivo","volume":"177","author":"Rogliani","year":"2020","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.rmed.2026.108743_bib32","doi-asserted-by":"crossref","DOI":"10.1016\/j.pupt.2019.101828","article-title":"Pharmacokinetics and pharmacodynamics of inhaled corticosteroids for asthma treatment","volume":"58","author":"Matera","year":"2019","journal-title":"Pulm. Pharmacol. Therapeut."},{"issue":"1","key":"10.1016\/j.rmed.2026.108743_bib33","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.pupt.2005.10.008","article-title":"Safety of inhaled corticosteroids: room for improvement","volume":"20","author":"Rossi","year":"2007","journal-title":"Pulm. Pharmacol. Therapeut."},{"key":"10.1016\/j.rmed.2026.108743_bib34","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.rmed.2017.01.006","article-title":"Optimizing drug delivery in COPD: the role of inhaler devices","volume":"124","author":"Rogliani","year":"2017","journal-title":"Respir. Med."},{"key":"10.1016\/j.rmed.2026.108743_bib35","first-page":"2433","article-title":"Airway deposition of extrafine inhaled triple therapy in patients with COPD: a model approach based on functional respiratory imaging computer simulations","volume":"15","author":"Usmani","year":"2020","journal-title":"COPD J. Chronic Obstr. Pulm. Dis."},{"issue":"6","key":"10.1016\/j.rmed.2026.108743_bib36","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1016\/j.chest.2016.07.035","article-title":"Dilemmas, confusion, and misconceptions related to small airways directed therapy","volume":"151","author":"Lavorini","year":"2017","journal-title":"Chest"},{"issue":"3","key":"10.1016\/j.rmed.2026.108743_bib37","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1164\/rccm.202406-1254CI","article-title":"Is disease stability an attainable chronic obstructive pulmonary disease treatment goal?","volume":"211","author":"Singh","year":"2025","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.rmed.2026.108743_bib38","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.2147\/PPA.S209532","article-title":"New insights to improve treatment adherence in asthma and COPD","volume":"13","author":"George","year":"2019","journal-title":"PPA"},{"issue":"1","key":"10.1016\/j.rmed.2026.108743_bib39","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1038\/s41533-021-00218-y","article-title":"Critical inhaler technique errors in Swedish patients with COPD: a cross-sectional study analysing video-recorded demonstrations","volume":"31","author":"Sulku","year":"2021","journal-title":"npj Prim Care Respir Med"}],"container-title":["Respiratory Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0954611126001113?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0954611126001113?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,4]],"date-time":"2026-04-04T12:40:38Z","timestamp":1775306438000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0954611126001113"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":36,"alternative-id":["S0954611126001113"],"URL":"https:\/\/doi.org\/10.1016\/j.rmed.2026.108743","relation":{},"ISSN":["0954-6111"],"issn-type":[{"value":"0954-6111","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"BDP\/FF\/GB single-inhaler triple therapy in COPD: real-world effectiveness, safety, and adherence in a pooled analysis of 5,000 patients","name":"articletitle","label":"Article Title"},{"value":"Respiratory Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rmed.2026.108743","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"108743"}}